<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04186208</url>
  </required_header>
  <id_info>
    <org_study_id>AAG-O-H-1633</org_study_id>
    <nct_id>NCT04186208</nct_id>
  </id_info>
  <brief_title>Non-interventional Study With NOVOCART® 3D for the Treatment of Cartilage Defects of the Knee in Pediatric Patients</brief_title>
  <acronym>JUNOVO</acronym>
  <official_title>Prospective, Non-interventional Study to Evaluate the Efficacy and Safety of NOVOCART® 3D for the Treatment of Cartilage Defects of the Knee in Pediatric Patients With Closed Epiphyses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tetec AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aesculap AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Winicker Norimed GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tetec AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter, single-arm non-interventional study to evaluate the efficacy,
      safety and health economics of NOVOCART 3D in the Treatment fo cartilage defects of the knee
      in pediatric patients wieh closed epiphyseal growth plates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study is a prospective, multicenter, single-arm non-interventional study to
      evaluate the efficacy, safety and health economics of NOVOCART® 3D in the treatment of
      cartilage defects of the knee in pediatric patients with closed epiphyseal growth plates.

      In this non-interventional study NOVOCART® 3D, which is marketed in Germany under Paragraph
      4b Medicinal Products Act, will be used in routine clinical practice according to the
      authorized Summary of Product Characteristics (SmPC). As stated in this SmPC, NOVOCART® 3D
      may only be used by physicians who are trained on the product. The treatment with NOVOCART®
      3D requires two surgeries. During the first surgery cartilage biopsies will be harvested
      arthroscopically and sent to TETEC AG (Tissue Engineering Technologies AG) for NOVOCART® 3D
      manufacturing, then NOVOCART® 3D will be transplanted during a second surgery about 3 to 4
      weeks later.

      All patients will be followed up for 5 years post NOVOCART® 3D transplantation and data will
      be collected at 3, 6, 12, 18, 24, 36, 48 and 60 months as outlined at the end of this
      synopsis.

      NOVOCART® 3D post treatment rehabilitation should follow the recommendations given in the
      SmPC and during product training.

      The primary and secondary variables (see below) will be assessed after a follow-up of 24
      month post NOVOCART® 3D transplantation (primary analysis).

      Long-term data will be assessed after an additional 3 years follow-up (follow-up analysis).

      The collected data will be documented using dedicated case report forms (CRFs) which are
      created and printed by TETEC AG.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2017</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Overall KOOS (Knee Injury and Osteoarthritis Outcome Score)</measure>
    <time_frame>24 months Follow Up (FU)</time_frame>
    <description>Change of KOOS defined as the average of the 5 subscale scores (range 0-100, higher values represent a better outcome)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of 5 subscores KOOS</measure>
    <time_frame>24 months FU</time_frame>
    <description>Change of the 5 subscores of KOOS (range 0-100, higher values represent a better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IKDC subjective</measure>
    <time_frame>24 month FU</time_frame>
    <description>Change of IKDC (International Knee Documentation Committee) subjective (range 0-100, higher values represent a better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain VAS</measure>
    <time_frame>24 month FU</time_frame>
    <description>Change in pain VAS (Visual Analogue Scale) (range 0-10, higher values represent a better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MOCART</measure>
    <time_frame>24 month FU</time_frame>
    <description>In vivo Performance via MRI (Magnetic Resonance Imaging), MOCART Score (Magnetic Resonance Observation of Cartilage Repair Tissue) (range 0-100, higher values represent a better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KOOS responder rate</measure>
    <time_frame>24 month FU</time_frame>
    <description>KOOS responder rate defined as Proportion of patients with &gt; 10 Points improvement in KOOS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IKDC subjective responder rate</measure>
    <time_frame>24 months FU</time_frame>
    <description>IKDC subjective responder rate defined as Proportion of patients with &gt;20.5 Points improvement in IKDC subjective</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with Treatment failures</measure>
    <time_frame>3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months</time_frame>
    <description>Proportion of patients with Treatment failures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economics variable (Days of missing work/school ) to NOVOCART 3D treatment</measure>
    <time_frame>3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months</time_frame>
    <description>Days of missing work/school due to knee pain/function issues in the target knee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economics variable (Days of hospitalization ) to NOVOCART 3D treatment</measure>
    <time_frame>3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months</time_frame>
    <description>Days of hospitalization due to knee pain/function issues in the target knee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economics variable (Number of postoperative doctor visits) to NOVOCART 3D treatment</measure>
    <time_frame>3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months</time_frame>
    <description>Number of postoperative doctor visits</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cartilage Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NOVOCART 3D</intervention_name>
    <description>Autologous Chondrocyte Implantation</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will include pediatric patients (&lt; 18 years of age) with closed epiphyses who
        suffer from a full-thickness cartilage defect of the knee caused by acute or repetitive
        trauma or by osteochondritis dissecans and who are scheduled for treatment with NOVOCART®
        3D. Further inclusion/exclusion criteria are given in the current version of the NOVOCART®
        3D SmPC, where the therapeutic indications, contraindications, special warnings and
        precautions for use are listed in detail.

        The decision to treat patients with NOVOCART® 3D must be made independently from the
        patient's participation in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  13 - 17 years old

          -  Medicinal indication for NOVOCART 3D treatment

        Exclusion criteria:

        • none
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Angele, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Regensburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Silvia Rombach, PhD</last_name>
    <phone>+4971211626</phone>
    <phone_ext>202</phone_ext>
    <email>silvia.rombach@tetec-ag.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandra Kirner, PhD</last_name>
    <phone>+4971211626</phone>
    <phone_ext>201</phone_ext>
    <email>alexandra.kirner@tetec-ag.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sportklinik Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden Württemberg</state>
        <zip>70372</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Becker, MD</last_name>
      <phone>+497115535</phone>
      <phone_ext>337</phone_ext>
      <email>becker-best@sportklinik-stuttgart.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Theresienkrankenhaus und St. Hedwig-Klinik GmbH</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68165</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Zimmermann, Prof. MD</last_name>
      <phone>+49621424</phone>
      <phone_ext>4254</phone_ext>
      <email>g.zimmermann@theresienkrankenhaus.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Orthophädie, Physikalische Medizin und Rehabilitation Knie- und Schulterorthopädie</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Müller, Prof. MD</last_name>
      <phone>+49894400</phone>
      <phone_ext>73781</phone_ext>
      <email>peter.mueller@med.uni-muenchen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der technischen Universität München</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Schmitt, MD</last_name>
      <phone>+494140</phone>
      <phone_ext>7821</phone_ext>
      <email>dr.schmitt@tum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univerisätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93047</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Angele, Prof. MD</last_name>
      <phone>+49941</phone>
      <phone_ext>6807</phone_ext>
      <email>peter.angele@klinik.uni-r.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Lubinus Clinicum Kiel</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tilmann Krackhardt, MD</last_name>
      <phone>+49431388</phone>
      <phone_ext>1120</phone_ext>
      <email>t.krackhardt@lubinus-stiftung.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 7, 2019</study_first_submitted>
  <study_first_submitted_qc>December 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cartilage defect</keyword>
  <keyword>knee</keyword>
  <keyword>pediatric patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cartilage Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

